Cytaright 1000mg Injection
Rx RequiredSalt Composition: Cytarabine
Expiry Date: 01/2028
Price on Request
Inclusive of all taxes
1 injection
About The Product
leukemia Cancer
Description
Cytaright 1000mg Injection is a chemotherapy based anticancer drug. It contains Cytarabine as an active ingredient that belongs to the antimetabolite class of drug.
It is used to treat certain types of leukaemias (a type of blood cancer with too many white blood cells), including acute myeloid leukaemia (AML) and chronic myelogenous leukaemia (CML). It also treats and prevents meningeal leukaemia as determined by the doctor.
It can be prescribed alone or with other chemotherapy medications.
Uses
- Acute myeloid leukemia (AML)
- Chronic myelogenous leukemia (CML)
- Meningeal leukaemia
Side Effects
Every medicine has some side effects that typically manage on their own as your body gets used to the medicine, but some people may experience severe side effects rarely. In that case, the patient should contact the doctor immediately.
Some common side effects of Cytaright 1000mg Injection include:
- Rash
- Skin ulcer
- Nausea
- Vomiting
- Hair loss
- Abdominal pain
- Anal ulcers
- Anemia (low number of red blood cells)
- Decreased white blood cell count
- Fever
- Infection
- Abnormal liver function
- Low blood platelets
- Mouth ulcer
- Pneumonia
- Sepsis
- Mouth sore
- Stomatitis (Inflammation of the mouth)
Contact your healthcare provider if you face any unusual or persistent side effects.
How To Use
- Cytaright 1000mg is available in injection form and is advised to be taken as per the doctor's prescription.
- It can be given under the skin (subcutaneous) into a vein (intravenously) into a muscle (intramuscularly) or the spine (intrathecal) by a doctor or nurse under strict medical supervision.Taking this injection in the wrong way may give you severe side effects.
- In case of overdose, contact your healthcare provider or doctor and they will provide you with medical attention. Missing or overdosing will impact the overall health of the patients and may also have side effects. So, it is always advisable to follow the prescription of the doctor strictly.
How It Works
- Cytaright 1000mg Injection is a cytotoxic drug that contains Cytarabine as an active ingredient. It works by primarily killing cancer cells by interfering with their DNA synthesis.
- It causes the DNA strands to cross-link, that stops the cells from dividing and ultimately leads to their death. Results in slowing or stopping the growth of cancer cells in your body.
Safety Advice
Avoid the consumption of alcohol while taking Cytaright 1000mg Injection, as alcohol can decrease the effectiveness of the medicine as well as worsen the symptoms.
Do not take Cytaright 1000mg Injection without consulting the doctor in case of pregnancy, as it can be unsafe to take it during this period.
Breastfeeding women should discuss the potential risks and benefits of the Cytaright 1000mg Injection with their healthcare provider before starting treatment.
Cytaright 1000mg Injection may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving.
Cytaright 1000mg Injection is safe for use in kidney disease if prescribed by the doctor. No dosage adjustment is necessary for this Tablet.
Share your medical history with the doctor before starting the Cytaright 1000mg Injection. Do not take it without consulting a doctor if you have any liver related issue.
FAQs
Cytaright 1000mg can be given under the skin (subcutaneous) into a vein (intravenously) into a muscle (intramuscularly) or the spine (intrathecal) by a doctor or nurse under strict medical supervision.
Reference
- Murphy, T., & Yee, K. W. (2017). Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. Expert opinion on pharmacotherapy, 18(16), 1765-1780.
- Baker, W. J., Royer Jr, G. L., & Weiss, R. B. (1991). Cytarabine and neurologic toxicity. Journal of Clinical Oncology, 9(4), 679-693.
- Löwenberg, B., Pabst, T., Vellenga, E., van Putten, W., Schouten, H. C., Graux, C. ... & Ossenkoppele, G. J. (2011). Cytarabine dose for acute myeloid leukemia. New England Journal of Medicine, 364(11), 1027-1036.
- Hamada, A., Kawaguchi, T., & Nakano, M. (2002). Clinical pharmacokinetics of cytarabine formulations. Clinical pharmacokinetics, 41(10), 705-718.
- El-Subbagh, H. I., & Al-Badr, A. A. (2009). Cytarabine. In profiles of drug substances, excipients and related methodology (Vol. 34, pp. 37-113). Academic Press.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
